// STATE LEGISLATION TRACKER

Missouri HB 2146: Modifies provisions relating to the operation of, and investment of moneys by, certain hospitals

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Missouri
Bill: HB 2146
Session: 2026
Filed: 2025-12-03
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

HB2146 is a hospital operations and investment bill, not a peptide or prescribing bill. Based on the title, subjects, and available text, it affects certain hospital powers and investment rules, with no direct impact on compounded peptides, telehealth peptide care, or clinician scope.

Key Points

No apparent change to access to compounded peptides.
No apparent change to off-label prescribing rules.
No apparent change to telehealth prescribing or visit requirements.
No apparent change to NP, naturopathic, or physician scope for peptides.
No apparent change to FDA 503A/503B compounding or Missouri PDMP rules.

What to Watch For

Note Hospital pharmacy subjects appear incidental; the bill is mainly about hospital operations and money management.

Note Peptide users should not treat this as changing prescription access or compounding legality.

Note Any later amendment adding pharmacy, prescribing, or controlled-substance language would need a fresh review.

Where the Bill Stands

The bill passed the House but was placed on the Senate Informal Calendar on May 7, 2026, and no final passage was reported.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws